Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia
Active, not recruitingOBSERVATIONAL
Enrollment
250
Participants
Timeline
Start Date
January 20, 2025
Primary Completion Date
June 30, 2026
Study Completion Date
March 31, 2027
Conditions
MyelomaLymphomaCLLMyelodysplastic SyndromeLeukemia Acute Myeloid - AML
Trial Locations (1)
Unknown
Tel Aviv Sourasky Medical Center, Tel Aviv
All Listed Sponsors
lead
Tel-Aviv Sourasky Medical Center
OTHER_GOV
NCT06944119 - Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia | Biotech Hunter | Biotech Hunter